Compare
Milestone Pharmaceuticals Inc. vs Korro Bio, Inc. vs Rafael Holdings, Inc. vs Rezolute, Inc.
| Latest fiscal year | Milestone Pharmaceuticals Inc. MIST | Korro Bio, Inc. KRRO | Rafael Holdings, Inc. RFL | Rezolute, Inc. RZLT |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-07-31 | 2026-06-30 |
| Revenue | n/a | $6.39M | $917.0K | n/a |
| Revenue growth (YoY) | n/a | +181.5% | +44.0% | n/a |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/m | n/m | n/a |
| Net margin | n/a | n/m | n/m | n/a |
| Net income | -$63.06M | -$117.26M | -$30.52M | -$77.59M |
| EPS (Diluted) | -$0.75 | -$12.48 | -$1.04 | -$0.75 |
| Operating cash flow | -$49.04M | -$78.56M | -$18.92M | -$64.64M |
| Free cash flow | -$49.34M | -$79.08M | -$18.93M | n/a |
| Cash & equivalents | $73.05M | $21.82M | $52.77M | $10.62M |
| Total assets | $113.56M | $113.51M | $114.11M | $112.85M |
| Total liabilities | $71.79M | $62.07M | $15.74M | $12.16M |
| Shareholders' equity | $41.77M | $51.44M | $98.37M | $100.69M |
| Return on year-end equity | -151.0% | -228.0% | -31.0% | -77.1% |
| Shares outstanding | 106.24M | 9.42M | n/a | 96.41M |
Revenue, most recent five fiscal years
| Fiscal year | Milestone Pharmaceuticals Inc. | Korro Bio, Inc. | Rafael Holdings, Inc. | Rezolute, Inc. |
|---|---|---|---|---|
| Latest | n/a | $6.39M Ended 2025-12-31 | $917.0K Ended 2025-07-31 | n/a |
| 1 year earlier | n/a | $2.27M Ended 2024-12-31 | $637.0K Ended 2024-07-31 | n/a |
| 2 years earlier | n/a | $0 Ended 2023-12-31 | $279.0K Ended 2023-07-31 | n/a |
| 3 years earlier | n/a | n/a | $410.0K Ended 2022-07-31 | n/a |
| 4 years earlier | n/a | n/a | $802.0K Ended 2021-07-31 | n/a |